Skip to main content

Table 1 Demographic and clinical characteristics

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Characteristic Second-line therapy
Total* Abiraterone acetate plus prednisone Cabazitaxel plus prednisone
Age N = 149 N = 100 N = 44
Median (range), years 72.6
(49.0–89.6)
73.9
(50.9–89.6)
69.7
(51.4–84.4)
≥75 years, n (%) 62 (41.6) 47 (47.0) 13 (29.5)
Prostate-specific antigen N = 147 N = 99 N = 43
Median (range), ng/ml 60.0
(0.9–3846.0)
42.8
(1.2–3222.0)
74.6
(0.9–3846.0)
Gleason score, n (%) N = 139 N = 92 N = 41
Median (range) 7 (4–10) 7 (4–10) 8 (6–10)
≤6, n/N (%) 27 (19.7) 24 (26.1) 2 (4.9)
=7, n (%) 47 (34.3) 30 (32.6) 17 (41.5)
≥8, n/N (%) 63 (46.0) 38 (41.3) 22 (53.7)
ECOG performance status, n (%) N = 122 N = 79 N = 40
0 31 (25.4) 22 (27.8) 7 (17.5)
1 70 (57.4) 46 (58.2) 24 (60.9)
2 20 (16.4) 10 (12.7) 9 (22.5)
3 0 (0.0) 0 (0.0) 0 (0.0)
4 1 (0.8) 1 (1.3) 0 (0.0)
Disease location, n (%) N = 150 N = 100 N = 44
Bone metastases 119 (79.9) 76 (76.0) 40 (90.9)
Visceral metastases 35 (23.5) 24 (24.0) 9 (20.5)
Main current comorbidities N = 150 N = 100 N = 44
Hypertension 80 (53.3) 52 (52.0) 26 (59.1)
Any cardiovascular disorder 22 (14.7) 18 (18.0) 3 (6.8)
Diabetes mellitus 26 (17.3) 17 (17.0) 8 (18.2)
Anemia N = 147 N = 97 N = 44
Yes, n (%) 31 (21.1) 16 (16.5) 15 (34.1)
LDH increased N = 130 N = 85 N = 39
Yes, n (%) 80 (61.5) 45 (52.9) 31 (79.5)
Alkaline phosphatase increased N = 140 N = 93 N = 41
Yes, n (%) 58 (41.4) 32 (34.4) 24 (58.5)
  1. ECOG, Eastern Cooperative Oncology Group; N, number of evaluable patients for each variable and group
  2. *Patients receiving treatments other than abiraterone acetate or cabazitaxel are not presented, but are included in the total sample. Therefore, the total sample is not only comprised of the pool of abiraterone acetate and cabazitaxel groups